Technical Analysis for GLYC - GlycoMimetics, Inc.
| Grade | Last Price | % Change | Price Change |
|---|---|---|---|
| F | 1.64 | -4.09% | -0.07 |
Earnings due: May 9
*** please verify all earnings dates ***| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Strong | Down | Down | Down |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Wide Bands | Range Expansion | 0.00% | |
| Oversold Stochastic | Weakness | 0.00% | |
| NR7 | Range Contraction | -4.09% | |
| Wide Bands | Range Expansion | -4.09% | |
| Gapped Down | Weakness | -4.09% | |
| Oversold Stochastic | Weakness | -4.09% | |
| Slingshot Bearish | Bearish Swing Setup | -11.59% | |
| Wide Bands | Range Expansion | -11.59% | |
| Gapped Up | Strength | -11.59% | |
| Oversold Stochastic | Weakness | -11.59% |
| Alert | Time |
|---|---|
| 60 Minute Opening Range Breakdown | about 19 hours ago |
| Down 3% | about 19 hours ago |
| Up 2% | about 22 hours ago |
| 1.5x Volume Pace | about 22 hours ago |
| Up 1% | about 23 hours ago |
Free Daily (Stock) Chart Reading
- Earnings date: 05/09/2024
GlycoMimetics, Inc. Description
GlycoMimetics, Inc., a clinical stage biotechnology company, focuses on the discovery and development of glycomimetic drugs to address unmet medical needs resulting from diseases. Its lead product includes GMI-1070, a glycomimetic drug candidate that acts as a pan-selectin antagonist has completed Phase II clinical trials for the treatment of vaso-occlusive crisis, a debilitating and painful condition that occurs periodically throughout the life of a person with sickle cell disease. The company is also developing GMI-1271, a specific E-selectin antagonist, which it plans to initiate a Phase I dose-escalation clinical trials in healthy volunteers to be used in combination with chemotherapy to treat acute myeloid leukemia and potentially other hematologic cancers. In addition, its drug candidates comprise GMI-1051 and other drug candidates for pseudomonas virulence factors. The company has a collaborative research and development agreement with Pfizer Inc. GlycoMimetics, Inc. was incorporated in 2003 and is headquartered in Gaithersburg, Maryland.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Biotechnology Disease Drug Discovery Acute Myeloid Leukemia Chemotherapy Clinical Trial Product Testing Pseudomonas Sickle Cell Disease Hematologic Cancers Nursing Research
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 3.5299 |
| 52 Week Low | 1.11 |
| Average Volume | 491,825 |
| 200-Day Moving Average | 2.07 |
| 50-Day Moving Average | 2.67 |
| 20-Day Moving Average | 2.32 |
| 10-Day Moving Average | 1.96 |
| Average True Range | 0.21 |
| RSI (14) | 26.47 |
| ADX | 33.9 |
| +DI | 10.78 |
| -DI | 31.69 |
| Chandelier Exit (Long, 3 ATRs) | 2.56 |
| Chandelier Exit (Short, 3 ATRs) | 2.25 |
| Upper Bollinger Bands | 3.16 |
| Lower Bollinger Band | 1.49 |
| Percent B (%b) | 0.09 |
| BandWidth | 71.98 |
| MACD Line | -0.29 |
| MACD Signal Line | -0.22 |
| MACD Histogram | -0.0673 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 1.84 | ||||
| Resistance 3 (R3) | 1.86 | 1.81 | 1.81 | ||
| Resistance 2 (R2) | 1.81 | 1.76 | 1.80 | 1.80 | |
| Resistance 1 (R1) | 1.73 | 1.73 | 1.70 | 1.71 | 1.79 |
| Pivot Point | 1.68 | 1.68 | 1.66 | 1.67 | 1.68 |
| Support 1 (S1) | 1.59 | 1.62 | 1.57 | 1.57 | 1.49 |
| Support 2 (S2) | 1.54 | 1.59 | 1.53 | 1.48 | |
| Support 3 (S3) | 1.46 | 1.54 | 1.47 | ||
| Support 4 (S4) | 1.44 |
